ALLIANCE PHARMA PLC
(“Alliance Pharma” or “the Company”)

Preliminary Results for the 10 month period ended 31 December 2005

Alliance Pharma plc (AIM: APH), the emerging speciality pharmaceutical company, is pleased to announce its preliminary results for the ten month period ended 31 December 2005. The results cover a 10 month period owing to a change to the Company’s year end to 31 December 2005, bringing the Company’s year end into line with that of its peers.

Financial Highlights

• Sales for the 10 month period of £12.28 million (12 months to 31 December 2004: £11.83m)
• Sales growth on an annualised basis of 24.6%
• Gross margin improvement to 54.3% (2004: 52.4%)
• Operating cashflow remains strong at £1.79 million (2004: £1.57m)
• Earnings before interest and tax of £2.17 million (2004: £2.26m)
• Pre-tax profit of £0.66 million (2004: £0.41m)

Operational Highlights

• Launch of Dental Products division and promotion of Periostat for periodontitis
• Launch of International Division for marketing of Periostat and Forceval
• Start of  Phase III clinical trials of Posidorm for sleep disorders
• Acquisition of Hydromol dermatology range post the year end

Commenting on the results, Michael Gatenby, Alliance Pharma’s Chairman, said: “During the period under review, Alliance has moved closer to its goal of delivering substantial and growing revenue streams from brands both acquired and developed in-house. All our efforts will continue to be directed towards achieving this goal.”

Read More...